Boston and Guidant merger gets shareholders' OK despite Xience setback
This article was originally published in Clinica
Executive Summary
Stockholders of Boston Scientific and Guidant have given the thumbs up to the companies' proposed merger, leaving US and EU regulatory approvals the only obstacles to the completion of the $27bn deal.